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1. Highlights: 
1. Pharmacokinetic resistance is a consequence of a drug not being delivered at 
sufficient concentration to, or with adequate distribution in, a tumour. The 
aberrant tumour microenvironment and vasculature influence drug delivery 
throughout the tumour; specific obstacles to drug distribution such as the blood-
brain-barrier may further limit drug delivery.  
2. Anticancer drugs also cause significant toxicity, again as a result of distribution 
to, and within, normal tissues. This will affect the nature and severity of the side 
effects that patients experience. 
3. Drug distribution and penetration through tumours and normal tissues may 
influence selection of the optimal candidate(s) during drug development as well 
as affecting the preferred dose and schedule of drug administration in clinical 
practice.  
4. MALDI-MSI is a technique for imaging the distribution of anti-cancer drugs and 
their metabolites within tumours that can be used in drug development to: 
4.1. Characterize drug distribution within the body to identify anticipated toxicities 
or target organs 
4.2. Define drug distribution within the tumour and its relationship with the tumour 
microenvironment and drug targets 
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4.3. Select the best drug candidate, dose, schedule or combinations based on tumour 
pharmacokinetic profile  
4.4. Facilitate proof-of-concept studies for new drug delivery systems. 
 
Abstract: 
Failure of systemic cancer treatment can be, at least in part, due to the drug not being 
delivered to the tumour at sufficiently high concentration and/or sufficiently 
homogeneous distribution; this is termed as ³pharmacokinetic drug resistance´. To 
understand whether a drug is being adequately delivered to the tumour, ³Srecision 
SKDUPDFRORJ\´techniques are needed. Mass spectrometry imaging (MSI) is a relatively 
new and complex technique that allows imaging of drug distribution within tissues. In 
this review we address the applicability of MSI to the study of cancer drug distribution 
from the bench to the bedside. We address: (i) the role of MSI in pre-clinical studies to 
characterize anti-cancer drug distribution within the body and the tumour, (ii) the 
application of MSI in pre-clinical studies to define optimal drug dose or schedule, 
combinations or new drug delivery systems, and finally (iii) the emerging role of MSI in 
clinical research. 
 
Keywords: MALDI-MSI, intra-tumoural drug distribution, drug development, 
pharmacokinetics 
 
 
 
1. INTRODUCTION 
Drug resistance, both de novo and acquired, is arguably the greatest challenge in 
oncology for cytotoxic chemotherapy, molecularly targeted agents (MTAs) and 
potentially also for immunotherapies. In addition to well recognized cellular and 
molecular mechanisms of resistance, the barriers that separate drug in the plasma from 
the cancer cell such as the aberrant tumour vasculature, the ³DOLHQ´PLFURHQYLURQPHQW
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with stroma rich in dysfunctional fibroblasts and extracellular matrix, areas of hypoxia 
and raised intratumoural fluid pressure all affect the concentration and distribution of 
drug within a tumour (Minchinton and Tannock, 2006). Failure of treatment due to the 
inability to deliver sufficient GUXJWRDVROLGWXPRXUKDVEHHQWHUPHG³SKDUPDFRNLQHWLF
drug UHVLVWDQFH´(Tannock et al., 2002).  
Precision medicine can be characterized as ³WKH ULJKW WUHDWPHQW IRU WKH ULJKW SDWLHQW
JLYHQDWWKHULJKWWLPH´; in the context of cancer drug development and pharmacology, 
this can perhaps be re-IRUPXODWHG DV ³WKH ULJKW GUXJ LQ WKH ULJKW SODFH DW WKH ULJKW
FRQFHQWUDWLRQ´:LWKGHYHORSPHQWV LQmatrix-assisted laser desorption/ionization mass 
spectrometry imaging (MALDI-MSI), intra-tumoural drug concentrations and 
distribution can now be studied. 
1.1 Pharmacology in oncology drug development 
Pharmacology data are typically characterized as pharmacokinetic (i.e. what the body 
does to the drug) and/or pharmacodynamic (i.e. what the drug does to the body). The 
latter has become increasingly important in modern drug development, involving 
imaging or the collection of blood, tumour or other surrogate tissues for novel 
biochemical or genetic analyses. By contrast, pharmacokinetic studies have remained 
focused on measurements of drug (and metabolite) concentrations, usually in plasma, 
albeit with increasingly sensitive assays. Remarkably little is, however, generally 
known about drug concentrations in the tumour (or other extravascular, normal tissues) 
and even less about how a drug is distributed within a tumour.  
In pre-clinical studies the IC50 is the concentration of a drug required to achieve half its 
maximum effect; for cytotoxics this relates to cytotoxicity but for molecularly targeted 
therapies the IC50 reflects binding to the specific target. These data are generated in 
vitro, with varying durations of drug exposure, bearing little if any resemblance to 
plasma pharmacokinetics in vivo or clinically, and not taking account of important 
factors such as protein binding of the drug. Nevertheless, comparisons are frequently 
made between the IC50 of a drug and plasma concentrations in patients and conclusions 
drawn as to whether a drug is more or less likely to be effective clinically.  
1.2. Intra-tumoural pharmacokinetics 
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The study of intra-tumoural drug concentrations and distribution is challenging. Tumour 
drug concentrations have been measured, albeit infrequently, in pre-clinical models or 
patient samples, but tumour disaggregation for LC-MS/MS analysis precludes 
generating information on drug distribution within the tumour. Whole body 
autoradiography (WBA), positron emission tomography (PET) and fluorescence 
microscopy (FM) have all been used to study drug distribution in pre-clinical models 
and occasionally in patients. These methods have the advantage of being less invasive 
than biopsy based assays, but both WBA and PET have low spatial resolution and 
require radiolabeled drug. FM allows the study of drug distribution at a cellular level 
but is limited to drugs that fluoresce naturally, unless a fluorescent label can be 
introduced; drug labelling can, however, be challenging since images may not 
differentiate between the drug and its metabolites and it can be argued that labelled drug 
may not behave in the same manner as the unlabeled compound (Cobice et al., 2015).  
1.2.1. Potential of MALDI-MSI in drug distribution studies  
Whilst many immunohistochemistry, autoradiography and spectroscopic methods are 
used routinely in pharmacology research, the application of MALDI-MSI is still 
relatively new. In MALDI-MSI images are created by irradiating the surface of a 
section of biological tissue, which has been coated with an energy absorbing matrix, 
with a UV laser. Ions ejected from the surface are subjected to mass spectrometric (MS) 
analysis and images generated by plotting the intensity of specific m/z values with 
positional information as a grey or colour scale (Swales et al., 2019).  One of the key 
features of MALDI-MSI that makes its use appealing is the ability to detect and study 
the distribution of multiple compounds simultaneously without the need for labelling. 
Additionally, by using accurate mass measurement and tandem MS analysis, molecules 
can be identified directly on tissue sections. The initial proof of concept study 
demonstrated the MALDI imaging of proteins in biological tissue more than 20 years 
ago (Caprioli, Farmer and Gile, 1997); since then, however, MALD-MSI has been 
applied to the analysis of a wide range of pharmaceutical compounds in situations 
ranging from whole animal sections to drug eluting stents and 3D tissue models 
(Prideaux, Staab and Stoeckli, 2010)(Swales et al., 2019)(Huang et al., 2012)(Russo, 
Lewis, et al., 2018). MALD-MSI can also relate the distribution of compounds to 
tumour morphology using conventional histology because MALDI-MSI does not 
disrupt or damage the sample. Limitations of MALDI-MSI include the requirement for 
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sample preparation and it only being applicable to molecules that can be ionized, 
although on-tissue derivatization has been employed to facilitate ionization. MALDI-
MSI also generates huge amounts of data requiring complex informatics resources for 
processing and analysis (Fuso Nerini et al., 2014)(Morosi, Zucchetti, et al., 2013). Until 
recently, spatial resolution was insufficient to study intra-tumoural drug distribution but 
resolution of 10-30µm is now routinely achieved with MALDI-MSI making such 
studies feasible. Finally, MALDI-MSI had previously been only semi-quantitative, but 
with recent advances some studies are now quantifying drug concentrations (Castellino, 
2012)(Takai et al., 2012)(Russo, Bricklebank, et al., 2018).  
To minimize the risk of failure later in cancer drug development there is a strong 
argument for undertaking proof-of-principle studies early to demonstrate that the active 
drug is delivered to the tumour in vivo, and in patients, at the necessary concentration; 
this is especially true for novel drug delivery systems. For example, several clinical 
trials were undertaken with early generation polymer-based pro-drugs before a proof-of-
principle pharmacokinetic study showed that MAG-CPT did not deliver camptothecin 
preferentially to the tumour in patients (Sarapa et al., 2003). In contrast, once Phase I 
trials with the oral fluoropyrimidine pro-drug capecitabine had been completed and 
demonstrated that circulating plasma levels of the parent compound and inactive 
metabolites were high but those of 5-fluorouracil (5-FU) very low (Mackean et al., 
1998), a proof-of-principle tumour/tissue pharmacokinetic study demonstrated that 5-
FU concentrations were 21-fold higher in tumour than plasma and, more importantly, 3-
fold higher in tumour than adjacent normal tissue (Schüller et al., 2000).  
We review the use of MALDI-MSI for analysis of the distribution of anti-cancer drugs 
in preclinical and clinical drug development, (Schöne, Hö and Walch, 2013)(Weaver, 
Hummon and Amanda, 2013). First, however, we give a brief summary of the technical 
aspects of MALDI-MSI to facilitate understanding the pre-clinical and clinical data; 
more detailed reviews of these technical aspects have been covered recently (Swales et 
al., 2019). 
1.2.2 Practicalities of MALDI-MSI  
Sample preparation is the crucial first step towards success in imaging an analyte. 
Samples are usually embedded in gelatin as MALDI-MSI works with cryotissues, 
which are usually sectioned at 10-12µm. Indeed, paraffin-embedding tissues makes it 
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impossible to ionize the sample properly. Parameters such as matrix selection and 
tissue-specific ion suppression have a significant impact on the sensitivity of analyte 
detection sensitivity. The type of matrix needs to be optimized for each analyte, which 
can be for positive or negative ionization, and then applied by spraying or spotting 
across the whole sample to extract the analyte from the upper layers of the tissue 
section. Once the sample is inside the MALDI-MSI spectrometer, the region of interest 
is selected for the laser beam to scan the tissue section. The matrix absorbs most of the 
energy of the irradiated laser leading to soft ionization of the analyte that allows the 
ionization of large molecules such as peptides or proteins. Each laser beam generates 
analyte ions that are separated by their time of flight (TOF) and mass-to-charge values 
(m/z), i.e. by their ³VL]H´ and ³FKDUJH´ ,RQL]HG DQDO\WHV DUH GHWHFWHG E\ WKH PDVV
spectrometer from each laser beam and the mass spectrum recorded. Each laser beam 
contains, therefore, the mass spectrum from analytes derived from that region of 
interest. Finally to obtain image of the analyte of interest, each DQDO\WH¶VP]is selected 
and the software translates the signal into a coloured pixel image. This creates D³PDS´
of the compound within the tissue. Tissue signals from different analytes can be later 
superimposed to create a composite image. Low mass ions from the matrix or 
endogenous compounds present in the biological tissue can, however, interfere with the 
target analytes. To avoid this interference, tandem mass spectrometry strategies 
(MS/MS) or high resolution mass spectrometry such as Orbitrap or Fournier transform 
ion cyclotron resonance (FTICR) can be applied (Schöne, Hö and Walch, 2013)(Römpp 
and Spengler, 2013). (Figure 1). 
 
2. PRECLINICAL STUDIES 
2.1. Characterizing anti-cancer drug distribution within the body and/or 
organs 
MALDI-MSI has been used to better understand anticancer drug distribution within the 
body and within specific organs with respect to potential toxicities.  
Whole body imaging of the microtubule targeted cytotoxic vinblastine in mice showed  
distribution mainly to the liver, kidney and tissue surrounding the gastrointestinal tract 
(Trim et al., 2008). Interestingly, however, the principal toxicities of vinblastine are 
AC
CE
PT
ED
 M
AN
US
CR
IPT
8 
 
myelosuppression and neuropathy; gastrointestinal toxicity is also common, reflecting 
biliary excretion (35%).  One technical aspect worthy of comment is that vinblastine 
imaging was subject to interference from other endogenous ions, especially in the renal 
cortex. To address this, the authors used MALDI-MSI-MS/MS mode to increase 
specificity; images were also compared with whole body autoradiography. When 
irinotecan (CPT-11) distribution was imaged in a mouse colorectal cancer model, high 
levels of drug and its active metabolite SN38 were detected in the intestinal tract and 
liver. CPT-11 is metabolized to SN-38 mainly in the liver and diarrhoea is, along with 
myelosuppression, the principle toxicity (Buck et al., 2015). Here again there was a 
high level of background noise when analysing SN38 with a MALDI-time-of-flight 
(TOF) MSI instrument, which could be improved with FTICR-MS. Although technical 
aspects are not the focus of this review, it is important to recognize the limitations of the 
technique that is being used and to select the most appropriate instrument and 
methodology.  
MALDI-MSI can also be useful to study drug distribution within a specific organ.  A 
study of imatinib and ifosfamide distribution successfully localized both drugs within 
the mouse kidney. Images of several phospholipids in the mouse kidney by MALDI-
MSI corresponded well to histological features of the kidney stained by haematoxylin-
eosin. Composite images of phospholipids, heme (a cofactor of hemoglobin used to 
delineate the lumen of the blood vessels) and imatinib were performed by MALDI-MSI; 
imatinib localized to the outer medulla, whereas ifosfamide accumulated in the inner 
medullary region (Römpp et al., 2011). Dasatinib also accumulated in the renal medulla 
of mouse kidney (Schulz et al., 2013). Another preclinical study with oxaliplatin, given 
by HIPEC (Heated IntraoPErative Chemotherapy) in rats, showed oxaliplatin and its 
metabolites were present almost exclusively in the renal cortex, not penetrating more 
deeply (Bouslimani et al., 2010),  although data on the duration of drug exposure were 
not reported. These studies demonstrate the limitations of knowing only to which organs 
a drug distributes, rather than where within a heterogeneous organ that accumulation 
occurs. 
Drug distribution is particularly important with respect to drugs that need to penetrate 
the intact blood brain barrier (BBB) to have their desired effect; by contrast, for other 
drugs it is desirable that they be excluded by the BBB to avoid toxicities. In the context 
of treating primary or metastatic brain tumours, it can be argued that drugs should be 
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excluded by the intact BBB but able to cross the disrupted blood-brain tumour barrier. 
Concentrations in the cerebrospinal fluid (CSF) have been used as a surrogate for drug 
penetration into the brain but this represents only drug that has crossed the choroidal 
plexus i.e. the blood-CSF barrier (Hawkins and Davis, 2005). By contrast, MALDI-MSI 
showed that irinotecan penetrated the blood CSF barrier but not the intact BBB in 
normal brain (Buck et al., 2015).   
Distribution of the Wee1 inhibitor MK-1775 was studied in glioblastoma orthotropic 
and heterotopic mouse xenografts using a MALDI-MSI TOF/TOF instrument. MK-
1775 MALDI-MSI images were generated for both MK-1775 and placebo (i.e. negative 
controls) animals with taken at the times of peak drug concentrations in the brain and 
blood. MK-1775 showed antitumour activity, as single agent or in combination with 
temozolamide, in the heterotopic model but not in the orthotropic model. Using 
MALDI-MSI, only 5% of the drug distributed into the normal brain but MK-1775 
distributed to both glioblastoma models; distribution was, however, more heterogeneous 
in the orthotropic tumours. This may explain, at least in part, the lack of activity in that 
model. Orthotropic brain tumours models may not, however, accurately represent the 
physiologic BBB in this setting as they do not have the intrinsic tumour vasculature and 
microenvironment. The alternative genetically engineered mouse model (GEMM) might 
be more representative of the physiological BBB, but such models are much more 
costly and have other limitations (Pokorny et al., 2015). Similar heterogenic distribution 
has been described with lapatinib in a model of breast cancer brain metastasis using 
autoradiography. In this model, brain-seeking 231-BR-HER2 cells were inoculated into 
the left heart ventricle; after 3-6 weeks brain metastases had developed and the animals 
had neurological symptoms. 14C-lapatinib was then administered orally or 
intravenously. Although brain metastases had 7 to 9-fold higher concentrations of 
lapatinib than normal brain, mean lapatinib concentration in the brain metastases was 
only 10 - 20% of that at other sites of metastasis (Taskar et al., 2012). Lapatinib is 
active against brain metastasis in patients with HER2 positive disease but that activity is 
limited, which may be in part due to relatively low intra-tumoural drug concentrations 
(Petrelli et al., 2017).  
A more complex study imaged BKM120 (a pan-class I PI3K inhibitor) and RAF265 (a 
RAF serine-threonine kinase inhibitor) simultaneously with heme in healthy mice and 
an orthotropic mouse model of glioblastoma. BKM120 drug signal did not co-locate 
AC
CE
PT
ED
 M
AN
US
CR
IPT
10 
 
with heme in the brain of the healthy mouse, indicating that, although separation 
between heme and the drug was not uniform, BKM120 penetrated the brain 
parenchyma. On the other hand, RAF265 brain distribution co-located with heme in the 
aberrant tumour vasculature but was not detected in normal brain parenchyma, 
indicating limited penetration through the normal BBB. Images of BKM120, RAF265 
and heme were performed by MALDI-MSI TOF/TOF, with the MALDI-MSI heme 
images validated by co-registration with fluorescence microscopy images of fluorescein 
and FTIC, two widely accepted vascular markers; 3-D models were reconstructed from 
MS and optical images (Liu et al., 2013).  
Finally, erlotinib and its metabolites were also imaged in a model of orthotopic glioma 
but using MALDI-FTICR to enhance sensitivity and specificity. Around the tumour 
margins, where there is local disruption of the blood-tumour barrier, there was a high 
intensity of heme signal while erlotinib was homogenously distributed independently of 
the heme signal indicating that at least some drug had escaped from the blood vessels 
(Liu et al., 2013). 
These examples show that improved MALDI-MSI technology can answer very specific 
questions about drug distribution, focusing on healthy tissues. If replicated in pre-
clinical models of cancer, this has the potential to inform drug development, improving 
the therapeutic window by reducing toxicity and increasing efficacy.    
2.2. MALDI-MSI studies of intra-tumoural drug distribution 
As discussed above, relatively little is known about the intra-tumoural drug distribution 
of most anticancer drugs but with improved spatial resolution it is becoming possible to 
characterize drug distribution using MALDI-MSI. 
To date, in vivo models of drug diffusion and distribution within tumour have been 
studied most extensively (Connell et al., 2015)(Huber et al., 2014). Such models are, 
however, complex and costly. Other options, such as injecting drugs directly onto 
tumour then imaging drug distribution by MALDI-MSI ex vivo complement in vivo 
models (Vegvari et al., 2013)(Connell et al., 2015) albeit with the limitation of 
disregarding the aberrant tumour vasculature. In vitro spheroid models also have 
limitations, specifically disregarding the complex tumour microenvironment and 
abnormal tumour vasculature, but nevertheless can be useful (Liu, Weaver and 
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Hummon, 2013)(LaBonia et al., 2016) and save both time and money in comparison 
with in vivo models.  
2.2.1. In vitro and ex-vivo studies 
Spheroids represent a three dimensional tissue culture model, where cancer cells are 
grown to form a small sphere; as such they are a rudimentary in vitro representation of a 
tumour mass with a vascularized area represented by the spheroid rim, a necrotic area at 
the spheroid core and a hypoxic area between the two. All three regions can be 
identified in slices through the spheroid and studied using MALDI-MSI.  
Irinotecan and its key metabolite SN38 have been identified in each of these three 
regions, localizing the metabolite to the spheroid rim where cells are active and dividing 
(Liu, Weaver and Hummon, 2013). HCT-116 colon cancer cell line spheroids of 
approximately 1mm diameter were treated with irinotecan, three regions of interest 
within each spheroid identified by optical imaging and each MALDI laser spot 
classified accordingly. Spheroids were first embedded in gelatin, 12µm thick sections 
transferred onto VOLGHVDQGĮ-cyano-4-hydroxycinnamic acid matrix used as this showed 
the less background interference with irinotecan. Irinotecan and SN38 images were 
generated using an AutoFlex III instrument with external calibration. Results were 
presented in 2D format with semi-quantitative data along with a colour scale to show 
drug intensity; both the parent and metabolite were imaged simultaneously. At initial (2 
and 6 hour) time points irinotecan was located in the rim and intermediate regions, but 
in the spheroid core only at the 12 hour time point. Drug distribution throughout the 
spheroids was achieved after 24 to 48 hours of exposure to irinotecan when central 
regions had a higher concentration of irinotecan than at the periphery. By contrast, SN-
38 and other metabolites were detected only after 72 hours of exposure, and the signal 
was more intense in the outer rim of the spheroids than at the core. Figure 2A. It is 
important to emphasize the complexity of this work and the detail of the analysis. The 
volume of data and the precision of the MALDI-MSI spheroid images achieve to 
generate drug distribution at multiple time points would be almost impossible in an in 
vivo experiment. Similar results were reported using a novel three dimensional printed 
fluidic device to study colorectal cancer spheroids exposed to irinotecan in combination 
with 5-fluorouracil and folinic acid and  imaged by MALDI-MSI TOF/TOF (Labonia et 
al., 2018).  
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Other work using spheroids has compared the penetration of conventional ³IUHH´  
doxorubicin to an ³LQ-KRXVH´ liposomal doxorubicin formulation using MALDI-MSI 
TOF/TOF instruments (Reeder et al., 2016). In this study, spheroid sectioning was 
performed with 16µm alternating slices, one for MALDI-MSI and the other for 
fluorescence microscopy analysis as doxorubicin fluoresce at 480nm. The images were 
overlayed by ImageJ, demonstrating the feasibility of combining the two 
methodologies; only MALDI-MSI could, however, image and distinguish doxorubicin 
from three doxorubicin metabolites (7-deoxydoxorubicinone, 7- deoxydoxorubicinolone 
and doxorubicinone). Spheroids treated with free doxorubicin had doxorubicin in the 
outer layers of the spheroid by 2 hours and it penetrated throughout the spheroids 
regions by 12 hours. A similar pattern was observed with liposomal doxorubicin but 
doxorubicin concentrations were higher in the outer rim than at the core at 12 hours, 
suggesting slower permeation of the liposomal formulation. No differences were seen in 
the distribution of doxorubicin metabolites between the two formulations. We have 
imaged paclitaxel in HCT-116 spheroids exposed to drug for 4 hours (Figure 2B) and 
shown rapid penetration throughout the spheroid (unpublished data).  
Patient derived organoids may represent better the heterogeneity of human cancers than 
conventional spheroids. Organoids derived from a patient with colorectal cancer 
exposed to irinotecan showed that the drug initially localized to the edge of the organoid 
but by 24 hours it had reached the core. The active metabolite SN38 was detected at 24 
hours but not at 6 hours, and did not co-locate with irinotecan; both compounds were 
imaged by MALDI-MSI TOF/TOF (Liu et al., 2017), and broadly supported earlier 
spheroid studies.    
Ex-vivo approaches have also been used with drug applied to human lung and breast 
cancers. An important landmark was the first human tissue drug imaging by MALDI-
MSI with spatial resolution of 30µm. Two first generations, clinically relevant, 
epidermal growth factor receptor (EGFR) inhibitors, erlotinib and gefitinib, were 
nanospotted onto sections of 3 different histological sub-types of non-small cell lung 
cancer using a MALDI LTQ Orbitrap XL mass spectrometer in MS/MS data collection 
mode. Drug signal intensity was higher in stroma than in tumour tissue for each of the 
tumour sub-types. The EGFR mutation status of the tumours was not reported so it is 
unclear whether the absence of such mutations contributed to the lower intratumoural 
drug concentrations (Marko-varga et al., 2011). Interestingly, in breast cancers exposed 
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to tamoxifen drug signal (again identified using a MALDI LTQ Orbitrap XL mass 
spectrometer) was higher in tumour than in stroma in oestrogen receptor (ER) positive 
tumours; the opposite was found  in ER negative tumours (Végvári et al., 2016).  
These in vitro and ex vivo studies show that MALDI-MSI can define biologically 
significant differences in the penetration and metabolism of anti-cancer drugs but are far 
removed from the clinical situation. It is, therefore important to understand how 
MALDI-MSI performs in more relevant in vivo models.  
2.2.2. In vivo studies 
In vivo studies of intra-tumoural drug penetration and distribution have the principle 
advantage of representing better drug pharmacokinetics (absorption, distribution, 
metabolism and excretion), the tumour vasculature and stroma and using a clinically 
relevant route of drug administration.  
An in vivo study of erlotinib distribution in a murine model of spontaneous pancreatic 
ductal carcinoma showed higher concentrations of the drug in healthy tissues than in the 
tumour. Genetically engineered murine models have the advantage of having an 
intrinsic tumour microenvironment and vasculature. Erlotinib was imaged with 
MALDI-MSI TOF/TOF instrument, with additional images obtained using a MALDI 
FTICR instrument to differentiate erlotinib and its metabolites. Areas with a higher 
proportion of atypical glands had a higher peak intensity of erlotinib than the stroma. To 
prove that differences in peak intensities were not due to ion suppression, ³RQ WLVVXH´
spotting of erlotinib was performed as a positive control. Survival of the mice did not 
correlate with overall erlotinib levels but did appear to correlate with the proportion of 
erlotinib in the atypical glands and with the percentage of those glands in the tumour 
(Grüner et al., 2016). A further MALDI-MSI and LC-MS/MS lung cancer murine 
xenograft study showed more heterogeneous distribution of erlotinib in the tumour, with 
less drug signal in necrotic areas, compared to normal lung. These findings were 
supported by MALDI-MSI and LC-MS/MS analysis of tumour resected from a patient 
with NSCLC and an activating EGFR mutation (Tsubata et al., 2017).  
MALDI-MSI can be useful not only to determine where a drug localizes but also how it 
distributes through a tumour in vivo over time. For example, in mice bearing colorectal 
cancer xenografts treated with sunitinib daily for 10 days, levels of sunitinib in the 
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tumour increased continuously up to day 7. By day 4, high levels of VXQLWLQLE¶Vactive 
metabolites were homogeneously distributed at the center of the xenografts. Similar 
levels and distribution of sunitinib were demonstrated when the drug was directly 
deposited onto the tissue surface ex vivo as described above. Temporal distribution of 
sunitinib and its metabolites was obtained using an orbitrap instrument. (Connell et al., 
2015).  
Drug distribution within tumour can be correlated with the vasculature by imaging a 
vessel marker such as CD31 in adjacent tissue sections, using immunohistochemistry or 
immunofluorescence, or by imaging heme with MALDI-MSI in the same section. 
Huber et al. (Huber et al., 2014) used immunohistochemistry to image CD31 and 
MALDI-MSI TOF/TOF to image erlotinib and afatinib in lung cancer xenografts, and 
sorafenib in a sarcoma xenograft model. Consecutive sections used for 
immunohistochemistry and MALDI-MSI where then superimposed with digital image 
analysis. Tumour regions associated with high drug levels correlated with areas of high 
vascularization, rich in small vessels. Furthermore, differential diffusion patterns were 
seen for the two drugs. Erlotinib concentration decreased in a linear fashion from the 
vessel up to a distance of 100µm then remained constant, whereas afatinib distribution 
plateaued 20µm from the blood vessel with concentrations then decreasing up to 140µm 
from the vessel (Huber et al., 2014).  
Likewise, the presence of drugs can also be correlated with their targets using either 
MALDI-MSI or techniques such as immunohistochemistry or immunofluorescence to 
image a GUXJ¶V receptor. Studies of EGFR inhibitors described above (Vegvari et al., 
2013)(Tsubata et al., 2017) did not report the mutational status of the tumours, which 
could potentially influence drug distribution. However, a recent study of the anaplastic 
lymphoma kinase (ALK) inhibitor alectinib in ALK amplified and wild type 
neuroblastoma xenografts found that drug distribution was heterogeneous and appeared 
not to be influenced by ALK status with alectinib imaged by MALDI-MSI MS/MS. In 
this experiment D8-alectinib (i.e. deuterated alectinib) was added to the matrix in order 
to correct possible ion suppression from endogenous tissue components or the matrix 
and, therefore, to verify the heterogeneity of alectinib distribution (Ryu et al., 2018). In 
another study using a colorectal xenograft model, composite images showed that some 
areas of the tumour with higher VEGFR2 expression had higher sunitinib 
concentrations. Sunitinib images were obtained using MALDI Orbitrap with VEGFR2 
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and other sunitinib targets imaged by immunofluorescence in serial sections (Torok et 
al., 2015).  
Another potential use for MALDI-MSI drug penetration studies may be in choosing 
between candidate lead compounds in pre-clinical drug development. Wide variability 
was found in the intra-tumoural distribution of a series of five anti-angiogenic receptor 
tyrosine kinase inhibitors in two murine colorectal cancer xenograft models (Torok et 
al., 2017). Motesanib, pazopanib, sorafenib, sunitinib and valatanib were imaged using 
a MALDI-MSI Orbitrap mass analyzer. In one model only sunitinib demonstrated clear 
biological activity. Interestingly, sunitinib also achieved the highest, and most 
homogeneous, intra-tumoural concentrations of the five inhibitors. In the other model a 
second inhibitor, vatalanib was detected at homogeneously high concentrations; again, 
there was a reduction in both tumour growth and angiogenesis.  
These studies are two dimensional representations of a three dimensional tumour. 
Recently, however, paclitaxel distribution and concentrations have been described in a 
xenograft model of malignant pleural effusion using serial two dimensional MALDI-
MSI TOF/TOF data to construct a three dimensional model with drug easily detected at 
the edge of the tumour but little if any paclitaxel in much of the xenograft, especially in  
necrotic or fibrotic areas (Giordano et al., 2016). 
Taken together, these in vivo studies show that it is possible to study drug distribution 
with MALDI-MSI and correlate drug distribution with tumour structure or with drug 
targets. The next question is if, and how, this information might be integrated into pre-
clinical drug development.  
 
 
2.3. Application of MALDI-MSI to pre-clinical oncology studies  
To measure drug concentrations with LC-MS/MS the tissue sample is homogenized, so 
all structural information is lost and the spatial distribution of drug within a tumour is 
not known. MALDI-MSI has the potential to establish proof-of-principle when testing 
different drug schedules, or drug delivery systems, and can be applied to both novel and 
established anticancer drugs. 
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Dose and treatment schedule, along with modification of the tumour microenvironment 
and novel drug delivery systems, can all influence the uptake and distribution of a drug 
(Minchinton and Tannock, 2006); regions of the tumour not exposed to optimal drug 
concentrations may then develop drug resistance leading to treatment failure (Tannock 
et al., 2002). Clinically, the goal is to maximize tumour drug delivery and efficacy 
without exacerbating toxicity. Drug distribution within a tumour may also be clinically 
relevant; although, one might expect that higher drug concentrations in a tumour would 
lead to JUHDWHU HIILFDF\ ³IDOVH positive´ results may occur if the drug is not evenly 
distributed.  
2.3.1. Drug dose and schedule 
In an example of how dose and schedule may be relevant a human melanoma xenograft 
model was treated with two different schedules/doses of paclitaxel, either 60mg/kg iv as 
a single dose or pre-treatment with 8mg/kg/day iv for 5 days and then a final dose of 
60mg/kg iv. The daily dose schedule appeared to not only achieve a higher 
concentration of paclitaxel in the tumours but drug distribution was also more 
homogenous when imaged by MALDI-MSI. Images here were obtained by a 
nanoparticle-assisted laser desorption/ionization mass spectrometry imaging technique, 
which used titanium dioxide (TiO2) nanoparticles matrix suspension to avoid 
heterogeneous matrix crystallization and to diminish background interference (Morosi, 
Spinelli, et al., 2013).  
2.3.2. Drug combinations 
Cesca et al. (Cesca et al., 2016) explored the combination of bevacizumab with 
paclitaxel in conventional ovarian and colon carcinoma subcutaneous xenografts and in 
an orthotropic model of ovarian carcinoma. They determined concentrations and 
distribution of paclitaxel by LC-MS/MS and MALDI-MSI TOF/TOF, respectively; 
modification of the tumour vasculature after administration of bevacizumab 
administration was studied immunohistochemically by staining for CD31 and by DCE-
MRI. Although the addition of bevacizumab enhanced the efficacy of chemotherapy, 
the intratumoural concentration of paclitaxel was lower in animals receiving the 
combination than in those treated with paclitaxel alone. Interestingly, however, the 
addition of bevacizumab was associated with more homogenous distribution of 
paclitaxel within the tumour when imaged by MALDI-MSI and slower efflux of drug 
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from the tumour which could explain the higher efficacy of the combination; these 
differences were not seen in normal tissues. Similar effects were seen with another 
cytotoxic, doxorubicin, VXJJHVWLQJ WKDW ³QRUPDOL]DWLRQ´ of the tumour vasculature 
enhanced efficacy. A second study in an EGFR mutant NSCLC xenograft model gave, 
however, contrasting results (Nishidate et al., 2017). Erlotinib penetrated tumour tissue 
well, with broad distribution within the tumour when imaged by MALDI-MSI, 
irrespective of co-administration of bevacizumab and appeared similar in both sensitive 
and resistant tumours.  
The tumour vasculature of animals pre-treated with bevacizumab appears to contain a 
higher percentage of small vessels (Morosi, Spinelli, et al., 2013) with more permeable 
endothelium (Yuan, 1998); there is also a correlation between the proportion of small 
vessels and tumoural drug levels in pre-clinical models (Huber et al., 2014). The 
microtubule inhibitor cytotoxic agent eribulin has other, non-cytotoxic effects in pre-
FOLQLFDO PRGHOV LQFOXGLQJ ³UH-PRGHOOLQJ´ RI WXPour vasculature (Funahashi et al., 
2014). This effect was confirmed in multiple pre-clinical models, but not with another 
microtubule inhibitor, vinorelbine (Ito et al., 2017). Interestingly, pre-treatment with 
eribulin (but not vinorelbine) also increased the accumulation of radio-labelled 
liposomal doxorubicin in an H1650 non-small cell lung cancer xenografts (Ito et al., 
2017); to date, however, MALDI-MSI studies of the impact of eribulin on drug delivery 
have not been published. The concept that modifying the tumour vasculature, leading to 
more homogeneous distribution of chemotherapy and greater efficacy, illustrates the 
potential clinical relevance of drug distribution studies. 
Inhibitors of the DNA damage repair enzyme poly-(ADP-ribose) polymerase (PARP) 
have been widely evaluated clinically, especially in patients with BRCA mutated and/or 
triple negative breast cancer (TNBC). Intra-tumoural penetration of one PARP inhibitor, 
veliparib, varied widely between and within TNBC xenografts (Bartelink et al., 2017). 
When administered with the DNA damaging cytotoxic carboplatin, intratumoural 
concentrations measured by LC-MS/MS correlated positively with platinum adduct 
formation, a clinically relevant pharmacodynamic marker. MALDI-MSI images of 
veliparib showed dose dependent penetration of veliparib into the tumour. This suggests 
that synergy between a PARP inhibitor and cytotoxic chemotherapy could be 
maximized by selecting a PARP inhibitor with optimal tumour penetration or by 
modifying the dose and/or schedule to enhance tumour penetration.   
AC
CE
PT
ED
 M
AN
US
CR
IPT
18 
 
MALDI-MSI has also been used to image cassette-dosed drugs, where multiple 
compounds are co-administered to mice bearing xenografts. This reduces the number of 
animals needed, and provides pharmacokinetic and drug distribution data at an early 
stage giving confidence that the compound is present at the site of action. Moreover, it 
is a useful tool for drug-drug pharmacokinetic interaction studies (Swales et al., 2014).   
2.3.3. Drug delivery systems 
Other strategies that have been adopted to improve drug delivery include new pro-drug 
delivery systems that selectively release the active ³ZDUKHDG´ LQ the tumour. 
Surprisingly, there has been little pre-clinical or clinical work to demonstrate that 
delivery systems such as nano-particles and antibody drug conjugates (ADC) actually 
do increase intra-tumoural drug concentrations, or improve drug distribution within 
tumours.  Albumin bound paclitaxel, nab-paclitaxel, enhances drug delivery in tumour 
xenografts compared to paclitaxel but no direct comparison between intra-tumoural and 
healthy tissue drug concentrations has been published (Desai et al., 2006; Chen et al., 
2015). Preclinical studies of trastuzumab emtansine (T-DM1, Kadcyla) demonstrated 
internalization of the ADC within HER2 positive cancer cells but, intratumoural drug 
concentrations were not reported (Barok, Joensuu and Isola, 2014; Diessner et al., 
2014). 
One relevant exception was a pre-clinical study with AQ4N, a pro-drug of a 
topoisomerase II cytotoxic designed to be activated in hypoxic regions within tumours, 
which did incorporate MALDI-MSI to study drug distribution in vivo. A proof-of-
principle study in mice bearing H460 xenografts demonstrated the release of AQ4, the 
active metabolite, in areas with low ATP as a marker of hypoxia. MALDI-MSI images 
of AQ4N, AQ4 and ATP showed little overlap between AQ4N and AQ4 with ATP 
having similar distribution to the AQ4N (Atkinson et al., 2007). Interestingly a 
companion early phase, translational clinical study confirmed the release of the active 
drug (detected by LC-MS/MS) in hypoxic tumour regions identified by Glut-1 staining 
(Albertella et al., 2008). (Figure 3) 
Another study compared conventional paclitaxel and paclitaxel incorporated in a 
micelle (NK105), designed to exploit the enhanced permeability and retention (EPR) 
effect that has been well described in relation to altered vasculature in pre-clinical 
tumour models. Distribution of paclitaxel was studied in a pancreatic cancer xenograft 
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model and in normal neural cells after treatment with NK105 or paclitaxel. Images of 
paclitaxel were obtained using MALDI-MSI with a combination of MS and MS/MS 
modes. NK105 delivered more paclitaxel to the tumour, and less to neural tissues, than 
conventional paclitaxel, and was associated with both greater efficacy and less 
neurotoxicity (Yasunaga et al., 2013). 
Finally, Fujiwara et al. (Fujiwara et al., 2016) studied another ADC comprising a 
monoclonal antibody against anti-human tissue factor, a transmembrane protein 
strongly expressed in various cancer and tumour vascular endothelia, linked to the 
highly potent cytotoxic monomethyl auristatin E. Using MALDI-MSI they 
demonstrated the release of monomethyl auristatin E in a pancreatic xenograft model. 
The release of the active compound was seen at 3, 24 and 72 hours after administration, 
with maximal drug accumulation at 24 hours and preferential accumulation in cancer 
cells rather than stroma. The authors advocated MALDI-MSI as a powerful tool for the 
design and pre-clinical optimization of ADCs. 
In conclusion, MALDI-MSI is a useful pre-clinical tool to investigate the impact of 
drug schedules and combinations on pharmacokinetic profiles in order to enhance drug 
delivery to tumours. Moreover, MALDI-MSI is applicable to the investigation of new 
drug delivery systems as a proof-of-principle technique where the prodrug and active 
compound can be imaged simultaneously.  
3. APPLICATION OF MALDI-MSI IN CLINICAL RESEARCH 
Although to date there are limited examples of MALDI-MSI in the clinical setting, it 
has the potential to be incorporated in early phase/translational clinical trials. The 
activity of anti-cancer drugs is invariably greater in pre-clinical studies than in clinical 
trials (in routine practice), due in part to the limitations of in vivo models (Mak, 
Evaniew and Ghert, 2014). Demonstrating the distribution of a drug, as well as its 
activity, at an early stage in clinical development would be helpful in driving 
progression to later stage clinical trials. 
We described above ex vivo MALDI-MSI studies of drugs in clinical samples (Végvári 
et al., 2016), but to date very few studies have explored the role of MALDI-MSI in 
patients with cancer. Distribution of the EGFR inhibitor erlotinib was studied in 
material obtained at autopsy from a patient with an EGFR mutated lung cancer. 
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MALDI-MSI showed that erlotinib was distributed to normal tissues and tumour in 
several organs but was not detected in the brain (Noda et al., 2015). Similar studies 
have been undertaken in tissues from patients with melanoma where vemurafenib drug 
distribution and BRAF expression have been correlated. BRAF V600E 
immunohistochemistry positive regions had a high vemurafenib signal when analyzed 
by MALDI-MSI, while it was undetectable in wild type BRAF tumours. Vemurafenib 
was also image by MALDI MS/MS mode correlating well the product ions with the 
precursor ion. (Kwon et al., 2015)(Sugihara et al., 2014).  
Preliminary results have been presented from a key phase I clinical trial in which the 
PARP olaparib was imaged by MALDI-MSI in seven biopsies taken from six patients. 
The drug signal detected by MALDI-MSI correlated well with the concentration of  
drug within the tissues when compared with LC-MS/MS data, and the distribution of 
olaparib was higher in areas of necrosis within the tumour (Shimoi et al., 
2014)(Yonemori et al., 2014).  
In the clinical setting, MALDI-MSI can also be useful also to understand the efficacy 
and toxicity of cancer drugs. For example, in one study biopsies were taken from skin 
and normal tissue in patients with pancreatic cancer treated with gemcitabine and 
erlotinib who had developed a skin rash. Erlotinib distribution was measured by 
MALDI-MSI and drug concentration by LC-MS/MS. Erlotinib was detected at higher 
concentrations in skin affected by the rash than in normal skin. (Nishimura et al., 2018). 
Figure 4. Another study of patients with gastric/gastro-esophageal junction cancer who 
received neoadjuvant chemotherapy reported a correlation between higher platinum 
concentrations, within the resected tumour, and response. Platinum concentrations were 
measured by LC-MS/MS, platinum distribution in tissue components by imaging mass 
cytometry and tissue collagen identified by trichrome staining. Surgical specimens from 
10 patients were available with tumour and adjacent ³QRUPDO´ tissues collected. High 
interpatient platinum tumour concentrations were observed which could be explained in 
part by platinum bound to tissue collagen (Cao, Chang, Cabanero, et al., 2018). A 
further study with imaging mass cytometry, in patients with colorectal cancer who had 
completed adjuvant oxaliplatin plus 5-FU (FOLFOX), showed deposition of platinum in 
skin biopsies from the lower legs up to 65.6 months after completing chemotherapy 
suggesting a possible mechanism of platinum sensory neuropathy (Cao, Chang, Zhang, 
et al., 2018).  
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CONCLUSIONS 
The characterization of drug concentrations, and in particular drug distribution, within 
tumours or normal tissues is a challenge that the rapidly developing technique of 
MALDI-MSI has started to address and may have an important role in drug 
development (Table 1).  
MALDI-MSI already has the potential to inform pre-clinical studies by comparing the 
penetration of candidate molecules into different regions of spheroids in vitro and 
xenografts in vivo. Similarly, in pre-clinical pharmacological and toxicological studies 
the presence of active compound at high concentrations in organs such as the kidney 
may be a concern, but that level of concern may be affected if the localization of drug to 
a particular region of the kidney could be determined by MALDI-MSI. Pre-clinical 
efficacy studies use doses, schedules, and combinations of drugs that are often 
determined empirically with little or no knowledge of tumour and normal tissue drug 
concentrations and distribution. MALDI-MSI has the potential to inform optimal dosing 
and/or scheduling of molecularly targeted agents, cytotoxics and immunotherapies to 
optimize tumour penetration and distribution. However, the area where MALDI-MSI 
has arguably the most immediate potential role is in the pre-clinical validation of pro-
drug delivery systems.  
The ultimate aim would be to incorporate MALDI-MSI studies in early clinical trials 
and recent studies suggest this is now becoming possible. Intra-tumoural drug 
distribution has been characterized in vivo using MALDI-MSI for a hypoxia activated 
pro-drug, an antibody drug conjugate, and a nanoparticle but clinical data have yet to be 
published and there are many more ADCs in development. Indeed, no such clinical 
proof-of-principle tumour pharmacokinetic data have been published for the clinically 
important ADC trastuzumab emtansine (Verma et al., 2012)(Krop et al., 2014), which is 
approved and widely used in the treatment of women with HER2 positive metastatic 
breast cancer or for nanoparticle albumin±bound paclitaxel (nab-paclitaxel), which is 
used to treat patients with breast, lung and pancreatic cancers (Rugo et al. 2015; 
Socinski et al. 2012; Von Hoff et al. 2013).  
In addition to the technical challenges for clinical MALDI-MSI studies, another 
potential limitation is the need for tumour biopsies. Such biopsies are, however, 
increasingly incorporated within early phase clinical trials either to identify the presence 
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of a molecular biomarker or to study PD endpoints and this should not be a major 
barrier to obtaining tumour biopsies for MALDI-MSI studies either from patients in the 
expansion cohort(s) of phase I trials or in a subsequent, specific tumour 
pharmacokinetic study.  
Preliminary results from the phase I olaparib trial suggest that we may be on the verge 
of using MALDI-MSI to deliver precision pharmacology, in other words ³WKH ULJKW
GUXJLQWKHULJKWSODFHDWWKHULJKWFRQFHQWUDWLRQ´ 
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Legends 
Figure 1. Typical workflow of a MALDI-MSI experiment. Matrix coated cryo-
sectioned tissue is placed at MADLI-MSI and region of interest is selected. The laser 
beam irradiates a selected section of a tissue impacting sample at each x and y co-
ordinate. Analytes travel according to TOF and m/z to the mass spectrometer where the 
mass spectrum is recorded for each x and y co-ordinate. Masses of interest are selected 
to generate images. This figure shows the image of ¶-deoxy-5-fluorouridine (5dFUR), 
a fluoropyrimidine metabolite, from a tumour section from an MDA-MB-231 xenograft 
treated with capecitabine (Jove et al., 2018). 
Figure 2. 3D Models of drug distribution with MALDI-MSI. (A). Time-dependent 
penetration of irinotecan (m/z 587) in HCT 116 spheroids analyzed by MALDI-IMS. 
Spheroids were treated with 20.6 ȝM irinotecan for 2, 6, 12, 24, 48, and 72 h (from left 
to right). For every treatment duration, color gradient intensity maps were generated 
from 7 consecutive 12 ȝm slices from a single spheroid in 120 ȝm vertical intervals (Liu, 
Weaver and Hummon, 2013). (B). Distribution of Taxol (Green) overlaid on 
endogenous PC lipid signal (red) in a HCT 116 spheroid after 4h treatment. 
Figure 3. MALDI-MS images showing the distribution of AQ4N, AQ4 and ATP in 
tumour tissue. (A) The position of the tumour, visualized by the phosphatidyl choline 
head group at m/z 184; (B) the distribution of AQ4N ([M+Na]+ (m/z 467)) overlaid 
against the distribution of AQ4 ([M+H]+ (m/z 413)); and (c) the distribution of ATP 
[M-H3PO4] (m/z 409) overlaid against the distribution of AQ4 [M+H]+ (m/z 413). The 
signal intensities of all ions imaged have been normalized against respective matrix 
ions. Controls for each compound can be seen on the right-hand side of the images. In 
(b) there is little overlap (which would be shown as yellow) between regions containing 
the prodrug AQ4N (green) and active compound AQ4 (red). Similarly, the overlap in 
(c) of the distributions of AQ4 and ATP is also found to be quite distinct. 
Figure 4. Representative molecular images of erlotinib distribution in skin rash and 
adjacent normal skin. (A) Hematoxylin and eosin staining of the adjacent normal skin 
including epidermis to deep dermis layers, which were concurrently collected at the time 
of rash biopsy. Scale bar = 500 ȝP (B) Determination of erlotinib distribution in the 
normal skin by mass spectrometry imaging. Molecular images were acquired at a step 
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VL]H RI  ȝP 6FDOH EDU LQGLFDWHV HUORWLQLE TXDQWLW\ SJSL[HO C) Hematoxylin and 
eosin staining of the rash, showing that inflammatory cells infiltrated into the papillary 
dermis and superficial-UHWLFXODUGHUPLV6FDOHEDU ȝPD) Molecular image of 
erlotinib distribution in the rash, indicating that erlotinib was predominantly localized in 
the superficial layer of the skin. (Nishimura, M. et al. 2018) 
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Table 1. Applicability of MALDI-MSI in drug distribution research 
$SSOLFDELOLW\RI0$/',-06,LQGUXJGLVWULEXWLRQUHVHDUFK 
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'UXJGLVWULEXWLRQZLWKLQ
ERG\DQGRUJDQV 
3.VWXGLHVLQYLYR 
 Possible toxicities 
 Organ site targets (CNS) 
,QFOLQLFDOUHVHDUFK 
-6WXGLHVRIGUXJGLVWULEXWLRQ
IURPSDWLHQW¶VWXPRXUWLVVXH
ELRSVLHVRUDXWRSVLHV 
'UXJGLVWULEXWLRQZLWKLQ
WXPRXU 
3UH-FOLQLFDOUHVHDUFK 
,QYLWUR 
 Understanding how the drug moves 
through solid tissue (3D tissue culture 
models) 
,QYLYR 
 Drug distribution and correlation with 
tumour structure (vessels, stroma). 
 Potential role to study drug interaction 
with its targets. 
 Diffusion of drug through the tumour. 
,QFOLQLFDOUHVHDUFK 
 Potential use of clinical samples to 
image drug in patients tumours. 
3URRI-RI-SULQFLSOHVWXGLHV 
8VHIXOIRUQHZGUXJGHOLYHU\V\VWHPVDQG
RSWLPLVDWLRQRIQHZVFKHGXOHVRUGUXJ
FRPELQDWLRQV 
3UH-FOLQLFDO 
,QYLYRVWXGLHVIRUGUXJGLVWULEXWLRQDUHXVHIXOWR
DQVZHU 
 Is the drug being delivered preferentially in the 
tumour than in other healthy tissues? 
 Is there a more homogeneous distribution, better 
retention or uptake within the tumour? Preclinical 
proof-of-principle for new drug delivery system, 
drug combinations or schedules. 
&OLQLFDO 
 As part of early phase clinical trials to confirm 
previous preclinical results before moving 
forward to phase II and III clinical trials. 
 Proof-of-principal clinical trials. 
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